CIK 0001069899 · Large accelerated filer
PHIBRO ANIMAL HEALTH CORP
Sign in to watch- Ticker
- PAHC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 131840497
- Phone
- 201-329-7300
- Business address
- GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD., SUITE 21, TEANECK, NJ, 07666
- Former names
- PHILIPP BROTHERS CHEMICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-09-30 | BENDHEIM JACK President and CEO | Sale 10b5-1 | −20,664 | $40.38 | $834K | 40,674 |
| 2025-09-19 | BENDHEIM JACK President and CEO | Conversion 10b5-1 | +30,000 | 61,338 | ||
| 2025-09-19 | BENDHEIM JACK President and CEO | Conversion · Class B Common Stock 10b5-1 | −30,000 | 20,136,034 | ||
| 2025-09-18 | BENDHEIM JACK President and CEO | Sale 10b5-1 | −7,022 | $40.26 | $283K | 31,338 |
| 2025-09-11 | BENDHEIM JACK President and CEO | Sale 10b5-1 | −3,520 | $40.95 | $144K | 38,360 |
| 2025-09-10 | BENDHEIM JACK President and CEO | Sale 10b5-1 | −3,520 | $41.29 | $145K | 41,880 |
| 2025-09-09 | BENDHEIM JACK President and CEO | Sale 10b5-1 | −14,080 | $40.33 | $568K | 45,400 |
| 2025-08-15 | Miller Larry Lee Chief Operating Officer | Grant or award | +5,184 | 35,184 | ||
| 2025-08-15 | Weinstein Judith See Remarks | Grant or award | +3,447 | 3,447 | ||
| 2025-08-15 | David Glenn Chief Financial Officer | Grant or award | +4,845 | 34,845 | ||
| 2025-08-15 | BENDHEIM Jonathan Director | Grant or award | +3,268 | 3,268 | ||
| 2025-08-15 | Bendheim Daniel M Exec. VP, Corporate Strategy | Grant or award | +3,964 | 3,964 | ||
| 2025-08-15 | BENDHEIM JACK President and CEO | Grant or award | +16,840 | 76,320 | ||
| 2025-08-15 | Escudero Lisa Ann See Remarks | Grant or award | +2,152 | 2,152 | ||
| 2025-08-15 | Andolino Anthony See Remarks | Grant or award | +1,793 | 1,793 | ||
| 2025-02-24 | CORCORAN E THOMAS Director | Purchase | +5,000 | $22.10 | $111K | 30,000 |
| 2025-02-09 | David Glenn Chief Financial Officer | Option exercise | +30,000 | 30,000 | ||
| 2025-02-09 | David Glenn Chief Financial Officer | Option exercise · Restricted Stock Units | −30,000 | 270,000 | ||
| 2024-09-04 | CORCORAN E THOMAS Director | Purchase | +5,000 | $20.02 | $100K | 25,000 |
| 2024-02-09 | David Glenn Chief Financial Officer | Grant or award · Restricted Stock Units | +300,000 | 300,000 |
Page 9 of 18 · 343 trades